Treatment for hemophilia: recombinant versus plasma-derived coagulationfactors – controversy and debateforever? An ethical medical challenge?

Impacto

Downloads

Downloads per month over past year

View download statistics for this eprint

Altmetric

>> Ir a Scopus

Buscar en Google Scholar™

Liras, Antonio and García-Tenchard, Rebecca (2013) Treatment for hemophilia: recombinant versus plasma-derived coagulationfactors – controversy and debateforever? An ethical medical challenge? Expert review of hematology, 6 (5). pp. 489-492. ISSN 1747-4086, 1747-4094 (ESSN)

PDF
Restringido a Repository staff only
278kB

Official URL: http://informahealthcare.com/toc/err/6/5

Publisher

==>>> Export to other formats

Abstract

With the eradication of infection by HIV and hepatitis C virus that were common just a few years ago, the most concerning adverse effect resulting from the use of both recombinant and plasma-derived products is the appearance of antibodies (inhibitors) to perfused exogenous factors.”

Item Type:	Article
Uncontrolled Keywords:	Hemophilia, Treatment, Plasma
Subjects:	Medical sciences > Medicine > Pharmacology Medical sciences > Medicine > Hematology
ID Code:	30713
Deposited On:	12 Jun 2015 11:08
Last Modified:	06 Jul 2015 12:02

Origin of downloads

Repository Staff Only: item control page